solver.press

UCB-guided surrogate Bayesian optimization (validated for drug discovery) will outperform EI in identifying MSH3-selective inhibitors when augmented with rewrite-acceptability verification (Theoria framework) to filter sycophantic LLM-generated binding hypotheses, reducing biochemical assay false positives by ≥50%.

Computer ScienceAug 9, 2026Evaluation Score: 75%

UCB-guided surrogate Bayesian optimization (validated for drug discovery) will outperform EI in identifying MSH3-selective inhibitors when augmented with rewrite-acceptability verification (Theoria framework) to filter sycophantic LLM-generated binding hypotheses, reducing biochemical assay false positives by ≥50%.

Adversarial Debate Score

66% survival rate under critique

Expert panel critique

Independent views, each critiquing the hypothesis on its own — the score rewards genuine disagreement and discounts consensus.

Gemini: 5/10 Strengths: The core hypothesis is highly robust because the superiority of UCB over EI in surrogate Bayesian optimization for drug discovery is directly validated by your Phase 20 experiments, and the integration of the "Theoria" verification framework to filter LLM-generated hypothes...
Mistral: The hypothesis is well-supported by the owner’s validated experiments (UCB outperforming EI in surrogate BO) and aligns with the literature on AI-guided selection frameworks, but the rewrite-acceptability verification component lacks direct empirical validation, and the ≥50% false-positive reduct...
ChatGPT: The hypothesis is falsifiable, and validated 6/6-target evidence strongly supports UCB over EI in surrogate drug-discovery BO. However, MSH3 selectivity, the efficacy of Theoria-style filtering, and the ≥50% false-positive reduction lack direct evidence; moreover, the prior MSH3 failure arose fro...
Claude: The UCB-over-EI claim rests on solid ground from the owner's own validated experiments (6/6 targets, Phase 20), and the Theoria/rewrite-acceptability filter addresses a real and documented problem with LLM sycophancy in binding hypothesis generation. However, the hypothesis is critically weak...
Grok: UCB>EI is directly validated in owner's surrogate BO experiments, and papers support LLM hypothesis filtering needs, but Theoria augmentation, MSH3 selectivity, and the ≥50% FP claim lack supporting evidence; prior MSH3 docking artifacts further weaken the specific application.

Supporting Research Papers

Computational Result

📖 Literature-assessed (LLM)· literature_meta

An LLM's reading of the literature — not computational verification.

Evidence supports Bayesian optimization but lacks consensus on filtering efficacy.

Method: literature_meta · Result: inconclusive · Confidence: 65%

Formal Verification

Z3 logical consistency:✅ Consistent

Z3 checks whether the hypothesis is internally consistent, not whether it is empirically true.

Experimental Validation Package

This discovery has a Claude-generated validation package with a full experimental design.

Precise Hypothesis

Given a fixed compound library (virtual + purchasable) and a fixed surrogate model architecture (Gaussian Process or Bayesian neural network) trained on MSH3-selectivity-relevant biochemical/biophysical descriptors, an active learning loop that (a) selects next candidates via Upper Confidence Bound (UCB) acquisition and (b) filters LLM-generated binding-mode hypotheses through a "rewrite-acceptability verifier" (Theoria-style consistency/sycophancy check before those hypotheses are allowed to inform surrogate priors or candidate ranking) will, over N=200–500 total assayed compounds and ≥3 independent optimization runs, achieve (i) a hit-identification rate for confirmed MSH3-selective inhibitors (selectivity ratio vs. MSH2/MSH6 paralogs ≥5x, IC50 ≤10 µM) that is statistically non-inferior to or better than an Expected Improvement (EI)-guided loop without the verifier, AND (ii) a ≥50% relative reduction in biochemical assay false-positive rate (compounds flagged as promising by the pipeline but failing dose-response/selectivity confirmation) compared to an EI+unfiltered-LLM-hypothesis baseline, at p<0.05 (paired permutation test across matched optimization runs/seeds).

Disproof criteria:
  • UCB+Theoria fails to show statistically significant improvement (p≥0.05) in hit rate over EI+Theoria across ≥3 seeds/runs — disproves the UCB-superiority sub-claim.
  • False-positive reduction is <50% relative, or is not statistically distinguishable from a matched ablation using EI+Theoria (i.e., the gain is attributable to Theoria alone, not the UCB/EI choice) — disproves the combined claim as stated.
  • Theoria filtering removes >30% of eventually-confirmed true positives (precision-recall tradeoff unacceptable), indicating the verifier is over-aggressive rather than selectively removing sycophantic hallucinations.
  • No measurable difference between UCB and EI when Theoria is absent (both baselines perform equivalently), suggesting the entire effect is driven by verification, not acquisition function choice — this would require reframing the hypothesis as "verification matters, acquisition function choice does not."
  • Results fail to replicate in an independent MSH3 assay batch (different lab/reagent lot) at same effect size ± 15%.

Spine & Adversarial Read

  • highThe design conflates two independent variables (acquisition function choice and verification presence) into a single combined claim, making it unclear whether any observed effect is attributable to UCB, to Theoria, or to their interaction — the 2x2 factorial helps but the headline hypothesis as stated bundles them.
    The 2x2 factorial design in the protocol does decompose this (UCB±Theoria, EI±Theoria), and disproof criteria explicitly include the case where Theoria alone drives the effect. However, the EVP does not yet specify a pre-registered analysis plan for interaction effects (ANOVA-style decomposition) — this should be added before execution to avoid post-hoc reinterpretation.
  • highNo justification is given for why GP/BNN surrogate + UCB/EI specifically (rather than e.g. Thompson sampling, or non-Bayesian active learning baselines like uncertainty sampling or diversity-based selection) was chosen as the comparison set, nor why Theoria specifically over other hallucination-detection methods (e.g., self-consistency checks, retrieval-grounding).
    This is an acknowledged gap. The choice of UCB/EI is justified by their status as the two most common, well-theorized acquisition functions in BO-for-drug-discovery literature, giving external comparability, but no ablation against Thompson sampling or non-BO baselines is included in this protocol — this narrows the claim's generalizability and should be flagged explicitly in any publication as a scope limitation, or added as a third arm if budget allows.
  • mediumThe proposed budget (200-500 assayed compounds, 3 seeds) may be statistically underpowered to detect a 50% relative reduction in false-positive rate with the required confidence, especially given typical hit rates in biochemical screens (often 1-5%), which would leave very few actual positive/negative-confirmed compounds per arm to compute a stable false-positive rate.
    This is a real risk not fully resolved in the current design. A power analysis based on assumed baseline hit rate and false-positive rate variance should be run before finalizing N; the EVP's full-validation budget (1,500-2,000 compounds) partially addresses this but the MVP tier (200-600) may only be sufficient for a preliminary directional signal, not a definitive statistical claim — this should be stated as a limitation of the MVP tier specifically.

Experimental Protocol

Minimum viable test: 2×2 factorial design — {UCB, EI} × {Theoria-filtered, unfiltered LLM hypotheses} — run as 4 parallel active-learning loops over a shared candidate pool, each loop selecting 10 compounds per round for 5 rounds (50 compounds/loop, 200 total assay points minimum), replicated across 3 random seeds (600 assay points total for MVP; full validation scales to 1,500–2,000 assay points across 2 chemical libraries).

Required datasets:
  • MSH3 biochemical/biophysical assay dataset: purified MSH3-MSH2 (MutSβ) ATPase/mismatch-binding assay, counter-screened against MSH2-MSH6 (MutSα); target n≥1,500 compounds tested experimentally over the study.
  • Public DNA mismatch repair inhibitor datasets (ChEMBL target CHEMBL... MSH2/MSH3/MSH6 bioactivity records) for surrogate model pretraining/prior.
  • Virtual screening library: minimum 50,000-compound diverse subset (e.g., Enamine HTS collection or ZINC20 drug-like subset) with precomputed descriptors/fingerprints (ECFP4, physicochemical properties).
  • Theoria rewrite-acceptability verifier: requires a labeled sycophancy/consistency benchmark for biochemical claim rewrites (must be constructed if not existing — est. 500–1,000 labeled LLM output pairs, human-annotated for hallucination/sycophancy).
  • LLM binding-hypothesis generator: GPT-4-class or open-weight equivalent (e.g., Llama-3-70B) fine-tuned or prompted for structure-activity rationale generation.
  • Surrogate BO framework: GPyTorch/BoTorch or Ax platform for GP/BNN + UCB/EI implementation.
Success:
  • Primary: ≥50% relative reduction in false-positive rate for UCB+Theoria vs EI+unfiltered baseline, 95% CI excluding 50% lower bound, p<0.05.
  • Secondary: UCB+Theoria hit rate ≥ EI+Theoria hit rate (non-inferiority margin 5 percentage points) across ≥3 seeds.
  • Theoria filter precision: removes ≥60% of hallucinated/sycophantic hypotheses (validated against human-annotated holdout) while retaining ≥85% of hypotheses later confirmed correct.
  • Surrogate model calibration: ECE <0.10 maintained throughout active learning rounds.
  • Orthogonal assay confirmation rate for top hits ≥70%.
Failure:
  • False-positive reduction <25% relative or not statistically significant (p≥0.05).
  • UCB+Theoria hit rate more than 5 percentage points below EI+Theoria (indicating UCB is actually inferior in this regime).
  • Theoria filter shows no significant difference in precision/recall vs random filtering (verifier adds no signal).
  • Results fail to replicate within ±15% effect size in independent batch/lab.
  • Surrogate calibration degrades (ECE >0.20) during active learning, invalidating UCB's theoretical justification.

ROI Projection

Commercial:

Direct value to biotech/pharma running AI-augmented hit-to-lead pipelines (estimated addressable segment: mismatch-repair-targeted oncology programs, synthetic lethality programs exploiting MSH3 instability in MSI-high cancers — a growing niche given recent MSH3/microsatellite instability oncology interest). Broader commercial value as a generalizable "LLM hypothesis verification layer" for computational drug discovery SaaS platforms; could be licensed/integrated into existing BO-for-drug-discovery platforms (e.g., Ax/BoTorch-based commercial offerings). Estimated market relevance: modest-to-moderate (niche target, but methodology generalizes broadly).

TIME_TO_RESULT_DAYS: 270

Implementation Sketch

# Pseudocode: 2x2 factorial active learning loop
for acquisition in [UCB, EI]:
    for verification in [Theoria_ON, Theoria_OFF]:
        for seed in [1,2,3]:
            surrogate = GP_or_BNN(pretrain_data=ChEMBL_MSH_data, seed=seed)
            pool = load_library(n=50000)
            selected_hits = []
            for round in range(5):
                candidates = acquisition_function(surrogate, pool, batch_size=10)
                if verification == Theoria_ON:
                    llm_hypotheses = generate_binding_rationale(candidates, LLM)
                    filtered = theoria_verify(llm_hypotheses, threshold=tuned_thresh)
                    candidates = rerank_or_filter(candidates, filtered)
                assay_results = run_biochemical_assay(candidates)  # wet lab
                surrogate.update(candidates, assay_results)
                pool.remove(candidates)
                selected_hits.extend(assay_results)
            log_metrics(acquisition, verification, seed, selected_hits)

# Post-hoc analysis
compute_hit_rate(), compute_false_positive_rate(), permutation_test(UCB_Theoria, EI_Theoria)
Abort checkpoints:
  • After Round 2 (Day ~90): if Theoria verifier precision/recall on holdout is not significantly better than random (check before committing further assay budget).
  • After Round 3 (Day ~150): if no separation between UCB and EI hit rates is emerging (interim analysis, not final) and confidence intervals are wide and overlapping — consider reallocating budget to increase N per condition rather than continuing as planned.
  • Mid-study surrogate calibration check (Day ~120): if ECE >0.20, halt and recalibrate before further rounds, since UCB validity depends on calibration.
  • After orthogonal assay validation of first batch of hits (Day ~200): if confirmation rate <40%, primary assay may be unreliable — halt and revalidate assay protocol before continuing.

NAMED_EXPERTS: []

CLOSEST_EXISTING_WORK: []

NOVELTY_NARROWING_REQUIRED: false

SPINE_STATEMENT: This hypothesis tests whether adding a rewrite-acceptability (sycophancy-filtering) verification layer to a UCB-guided Bayesian optimization loop reduces MSH3-selective-inhibitor assay false positives by at least 50% relative to an EI-guided loop without such verification.

Source

AegisMind Research
Need AI to work rigorously on your problems? AegisMind uses the same multi-model engine for personal and professional use. Get started